

Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium

Event Schedule

Mon, Nov 29, 2021

11:00am

Introduction

🕒 11:00am - 11:05am, Nov 29

🗣️ Speaker



Dr. Andrea van Elsas Abata Therapeutics and Third Rock Ventures, Cambridge, MA

11:05am

Butyrophilins and V γ 9V δ 2-T cells: translating immune regulation to patients' treatments

🕒 11:05am - 11:30am, Nov 29

Prof. Olive's presentation will address the roles of BTN3A and BTN2A1 in human primary tumors and will mainly focus on V γ 9V δ 2 T cell and cancer cells as well as their regulation, function and roles as biomarkers.

🗣️ Speaker



Prof. Daniel Olive Imcheck and Aix-Marseille Université, Marseille, FR

11:30am

Mastering T cell diversity for a successful clinical translation

🕒 11:30am - 11:55am, Nov 29

Overall, $\gamma\delta$ T cells display potent cytotoxicity, which usually does not depend on tumour-associated (neo)antigens, towards a large array of haematological and solid tumours, while preserving normal tissues. However, the precise mechanisms of tumour-specific $\gamma\delta$ T cells, as well as the mechanisms for self-recognition, remain poorly understood. Also a large diversity in terms of receptors and function is observed in this population. In this presentation, I therefore discuss functional diversity and diversity of subsets as well as receptors which I consider as major challenges but also opportunities for the clinical implementation of cancer immunotherapies based on $\gamma\delta$ T cells and their receptors.

Nat Rev Drug Discov. 2020;19:169-184

🗣️ Speaker



Prof. Jürgen Kuball University Medical Center, Utrecht, NL

11:55am

Allogeneic T cell therapies

🕒 11:55am - 12:20pm, Nov 29

🗣️ Speaker



Dr. Michael Koslowski GammaDelta Therapeutics, London, UK

12:20pm

Bispecific antibodies to engage V γ 9V δ 2-T cells for cancer immunotherapy

🕒 12:20pm - 12:45pm, Nov 29

V γ 9V δ 2-T cells constitute the largest $\gamma\delta$ -T cell subset in human peripheral blood and are powerful anti-tumor immune effector cells. V γ 9V δ 2-T cell based cancer immunotherapy approaches explored thusfar demonstrated a good safety profile and incidental antitumor activity. In this presentation I will discuss the generation and characterization of bispecific antibodies (Gammabody™ platform) designed to trigger tumor-specific cytolytic activity of V γ 9V δ 2-T cells. The potential of this approach for the treatment of solid tumors will be illustrated using an EGFR- $\gamma\delta$ bispecific T cell engager (bsTCE) and for hematological malignancies using the CD1d- $\gamma\delta$ bsTCE LAVA-051, which is currently evaluated in a first-in-human clinical Phase 1/2a study in patients with CD1d-expressing CLL, MM, or AML refractory to prior therapy (NCT04887259).

🗣️ Speaker



Prof. Hans van der Vliet LAVA Therapeutics and Amsterdam UMC, Utrecht, NL

12:45pm

Break

🕒 12:45pm - 1:00pm, Nov 29

1:00pm

Discussion panel

🕒 1:00pm - 1:45pm, Nov 29

🗣️ Speakers



Prof. James Allison MD Anderson, Houston, TX



Prof. Padmanee Sharma MD Anderson, Houston TX



Prof. Daniel Olive Imcheck and Aix-Marseille Université, Marseille, FR



Prof. Jürgen Kuball University Medical Center, Utrecht, NL



Dr. Michael Koslowski GammaDelta Therapeutics, London, UK



Prof. Hans van der Vliet LAVA Therapeutics and Amsterdam UMC, Utrecht, NL

1:45pm

Wrap up by Dr. Andrea van Elsas

🕒 1:45pm - 2:00pm, Nov 29

🗣️ Speaker



Dr. Andrea van Elsas Abata Therapeutics and Third Rock Ventures, Cambridge, MA